MIST
MIST clinical trials: Milestone Pharmaceuticals Inc.
Every trial on ClinicalTrials.gov where Milestone Pharmaceuticals Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 9
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MIST on the catalyst calendar · MIST registry changes
- Primary completion Dec 2028Sponsor estimatePhase 3NCT06716021ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3Milestone Pharmaceuticals Inc. · Atrial FibrillationRecruitingMISTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2027Sponsor estimatePhase 2NCT05763953The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)Milestone Pharmaceuticals Inc. · Paroxysmal Supraventricular TachycardiaRecruitingMISTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2026ActualPhase 3NCT04952610Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular TachycardiaMilestone Pharmaceuticals Inc. · Paroxysmal Supraventricular TachycardiaCompletedMISTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2020ActualPhase 3NCT03635996Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302Milestone Pharmaceuticals Inc. · Paroxysmal Supraventricular TachycardiaTerminatedMISTLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2023ActualPhase 2NCT04467905ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2Milestone Pharmaceuticals Inc. · Atrial FibrillationCompletedMISTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2023ActualPhase 3NCT03464019Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).Milestone Pharmaceuticals Inc. · Paroxysmal Supraventricular TachycardiaTerminatedMISTLeadIQVCollaboratorMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2023ActualPhase 3NCT04072835Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303Milestone Pharmaceuticals Inc. · Paroxysmal Supraventricular TachycardiaCompletedMISTLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 2NCT02296190Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus RhythmMilestone Pharmaceuticals Inc. · Paroxysmal Supraventricular Tachycardia (PSVT)CompletedMISTLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2020ActualNo phase registeredNCT03353610The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.Milestone Pharmaceuticals Inc. · Paroxysmal Supraventricular Tachycardia (PSVT)TerminatedMISTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2, 2024ActualPhase 3NCT05410860Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal...Corxel Pharmaceuticals · Tachycardia, SupraventricularCompletedMISTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2023ActualPhase 1NCT05511870A Study of Etripamil in Healthy SubjectsCorxel Pharmaceuticals · Healthy Chinese SubjectsCompletedMISTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner